Collegium Pharma (COLL) Misses Q4 EPS by $1.77
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- Nasdaq, S&P 500 futures rise ahead of key jobs report
- Oil rallies for the week as U.S.-Iran fighting resumes; diesel hits record high
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- Fed’s Waller open to September rate hold - if disinflation holds up
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Collegium Reports Fourth Quarter and Full-Year 2021 Financial Results
February 24, 2022 4:01 PM ESTBDSI Acquisition Expected to Close Late Q1 2022
2022 Revenue Guidance of $315-$330 Million, Growth Driven by Xtampza ER
Full-Year Net Income of $71.5 Million and Full-Year Adjusted EBITDA of $118.3 million
Cash Balance of $186.4 Million
Conference Call Scheduled for Today at 4:30 p.m. ET
STOUGHTON, Mass., Feb. 24, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc.... More
